Vaso Corporation (VASO)

[ProfitScout]

Vasomedical to Present at Rodman & Renshaw Techvest Seventh Annual Healthcare Conference

WESTBURY, N.Y., Nov 02, 2005 (BUSINESS WIRE) -- Vasomedical, Inc. ( VASO ), a leader in the noninvasive treatment and management of cardiovascular diseases, today announced that Thomas Glover, president and chief executive officer of Vasomedical, is scheduled to present at the upcoming Rodman & Renshaw Techvest Seventh Annual Healthcare Conference. The presentation is currently scheduled for 11:15 a.m. (Eastern Time) on Wednesday, November 9, 2005. The event will be held from November 7-9, 2005 at the New York Palace Hotel in New York.

Individuals may listen to a live web cast of the presentation by accessing the following link: http://wsw.com/webcast/rrshq7/vaso/ or by visiting the Company's web site at www.vasomedical.com, under the investor relations tab. The presentation will be archived for a limited time.

The conference will feature presentations from more than 290 public and privately held emerging growth healthcare companies presenting data on an array of therapeutic topics including oncology, cardiovascular diseases, central nervous system disorders, infectious diseases and medical device technologies. The conference aims to provide investors, both specialists and generalists, with the opportunity to meet with institutional investors, corporate executives and experts from the scientific and medical communities. The three-day conference will include company presentations, breakout sessions, Q&A, and one-on-one meetings with presenting companies. Details regarding the conference can be obtained at www.rodmanandrenshaw.com.

About EECP(R) Therapy

EECP external counterpulsation therapy is typically given in 35 one-hour sessions over seven weeks. Patients recline on a contoured treatment table and their calves, lower thighs and upper thighs are wrapped in a pneumatic cuff set. The system, which is synchronized to the individual patient's cardiac cycle, inflates the cuffs with air to create external pressure when the heart is resting and deflates the cuffs just before the next heartbeat. The system's action, which pulses counter to the heart's beating, increases blood flow to the heart muscle and other organs and decreases the heart's workload, creating a greater oxygen supply for the heart muscle while lowering its need for oxygen.

About Vasomedical, Inc.

Vasomedical, Inc. is primarily engaged in designing, manufacturing, marketing and supporting EECP external counterpulsation systems based on the Company's unique proprietary technology. EECP therapy is a noninvasive, outpatient therapy for the treatment of diseases of the cardiovascular system currently indicated for use in cases of stable or unstable angina, congestive heart failure, acute myocardial infarction and cardiogenic shock. The therapy serves to increase circulation in areas of the heart with less than adequate blood supply and may restore systemic vascular function. The Company provides hospitals, clinics and private practices with EECP equipment, treatment guidance and a staff training and equipment maintenance program designed to provide optimal patient outcomes. Additional information is available on the Company's website at http://www.vasomedical.com.

EECP is a registered trademark for Vasomedical's enhanced external counterpulsation systems.

Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this report, words such as "anticipated," "believes," "could," "estimates," "expects," "may," "plans," "potential" and "intends" and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the following: the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; and the risk factors reported from time to time in the Company's SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.

SOURCE: Vasomedical, Inc.

Vasomedical, Inc.
Thomas W. Fry, 516/997-4600
[e-mail]
or
Investor Relations:
Lippert/Heilshorn & Associates, Inc.
Kim Golodetz, 212/838-3777
[e-mail]
or Bruce Voss, 310/691-7100
[e-mail]


Copyright Business Wire 2005